New Rule Shifts Drug Safety Reporting Start Date

India's Central Drugs Standard Control Organisation (CDSCO) is changing how drug safety reports are filed. Pharmaceutical companies and importers must now begin submitting Periodic Safety Update Reports (PSURs) from the drug's actual market launch date, not when it was approved. This new rule aims to fix a problem where a long gap between approval and launch meant vital real-world safety data wasn't collected promptly. By starting PSURs at launch, the CDSCO wants to ensure safety monitoring keeps pace with when patients actually use medicines. This change aligns with global efforts for stronger, faster post-market safety checks, similar to requirements from the European Medicines Agency (EMA). The goal is to avoid losing 'valuable safety insights' needed for identifying side effects and managing drug risks from the very beginning of a medicine's time on the market.

Global Standards and India's Growing Pharma Market

Worldwide, PSURs are a key part of drug safety monitoring, helping regulators evaluate a medicine's long-term risk versus benefit. For example, the European Union requires PSURs at set times after a drug is approved, which is a major part of its oversight. In the U.S., while not all devices require formal PSURs, strong post-market tracking and adverse event reports are mandatory. By linking PSURs to market launch, India is moving closer to these global standards that stress collecting real-world data from the start. The Indian pharmaceutical industry, known as the 'pharmacy of the world,' already operates in a complex regulatory landscape. Besides PSURs, companies must also comply with new rules on Good Manufacturing Practices (GMP), bio-equivalence tests, and traceability, all contributing to rising compliance costs. These combined demands, while meant to improve drug quality and global standing, can hit smaller manufacturers harder. India's drug market is worth about $65 billion by volume and is expected to hit $130 billion by 2030. Strong exports, with nearly 70% going to strict markets, fuel this growth. The CDSCO's new rule adds another layer to these complex requirements, forcing drugmakers to carefully match their launch plans with prompt safety reporting.

Compliance Challenges for Drugmakers

Although the CDSCO's rule aims for patient safety, drug companies, especially smaller ones, will face higher operational and financial costs. Meeting PSUR deadlines from the actual launch date means companies need efficient internal processes, strong data management, and earlier investment in safety monitoring. This burden is made heavier by other ongoing regulatory changes in India, like stricter GMP rules and digital reporting requirements, which already strain compliance budgets. Companies that fail to align their market entry with ready pharmacovigilance systems risk penalties or delays in managing their products. Moreover, the demand for full safety data from day one might slow market entry if companies delay launching until their surveillance systems are fully operational. This could put companies with weaker safety monitoring systems at a disadvantage compared to larger domestic or international players. Past regulatory hurdles in India have shown that high compliance costs can affect how affordable and accessible medicines are. The new PSUR timeline adds to these worries, requiring careful planning to manage the increased pressure.

Adapting to New Reporting Rules

India's evolving regulatory environment is demanding more accountability and proactive safety monitoring. Drug companies must now include PSUR planning in their pre-launch strategies, rather than viewing it as a simple administrative task after approval. This will require better teamwork across regulatory affairs, R&D, and commercial departments. As India grows as a major global drug supplier, being agile with regulations will be crucial for success. Companies that can quickly adjust their launch and safety monitoring processes to meet these higher standards will be better positioned to succeed in the Indian market and stay competitive.